Arrow Dx has been selected as one of the 15 companies that will compete in the 2020 $200K M2D2 Challenge in Lowell, MA in Fall 2020. The 2020 $200K M2D2 Challenge received 250+ applications this year.
Main Content
Technology Platform
Arrow Dx is developing highly sensitive detection chips that can be incorporated into portable sensors. The versatility of our technology allows for use in a variety of applications ranging from early disease detection to environmental pollutant detection to quality control in the wine industry.
Blood Diagnostics
The ability to detect small molecules, viruses, bacteria and proteins in blood is an important tool in the fight against disease. Our proprietary technology allows for an enhanced detection method necessary for the early diagnosing of many diseases such as COVID-19, E.coli, and non-alcoholic fatty liver disease (NAFLD) such that an effective treatment can be found thus making it easier for both the patient and physician.
Protein Applications
Protein conformational changes are often a strong indicator of a medicine’s effectiveness on an individual patient. Arrow Dx is currently developing methods to apply its technology to further the development of biopharmaceuticals and the pursuit of enhanced personalized medicine.
Machine Learning
Our mission is to harness the powerful applications of machine learning and predictive analytics to enhance diagnostic medicine. Using proprietary algorithms we are working to develop single protein and metabolite sensitivity.
Arrow Dx initiates efforts to develop quick, inexpensive, sensitive diagnostics for viruses such as COVID-19, H1N1 as well as bacteria such as E.coli.
Arrow Dx attends the 2018 J.P. Morgan Healthcare Conference.
Joe DiStefano III, PhD, Distinguished Professor of Computer Science and Medicine, Univ. of Ca., Los Angeles joins Scientific Advisory Board.